At Strongbridge Biopharma, our focus on rare diseases has resulted in a portfolio of innovative treatments for rare neuromuscular and endocrine conditions, including the commercialization of Macrilen and KEVEYIS in the U.S.
At Strongbridge Biopharma, we are committed to delivering better results for patients, healthcare providers, employees, and investors.
The Strongbridge team is passionate about making a positive difference in the lives of patients with rare diseases. It’s why we’re here.
© 2019 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V14 08/2018